Tovecimig Biosimilar Bispecific Antibody (VEGF-A) for Research

Cat No.: GMP-Bios-INN-1424

Anti-VEGFA therapeutic antibody (Pre-made Tovecimig biosimilar,Bispecific Mixed mAb and scFv) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tovecimig (development codes ABL-001/CTX-009) is a humanized bispecific antibody targeting VEGF-A (VEGFA) and DLL4. It is developed by ABL Bio and Compass Therapeutics and Elpiscience Biopharmaceuticals and National OncoVenture and University of Texas M. D. Anderson Cancer Center and TRIGR Therapeutics for Biliary cancer, Colorectal cancer in Phase II/III development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1424-1mg 1mg
GMP-Bios-INN-1424-10mg 10mg
GMP-Bios-INN-1424-100mg 100mg
GMP-Bios-INN-1424-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Tovecimig biosimilar, Bispecific Mixed mAb and scFv, Anti-VEGFA Antibody: Anti-VEGFA/Vascular endothelial growth factor A/long form/L-VEGF therapeutic antibody
INN Name Tovecimig
Target VEGFA
Format Bispecific Mixed mAb and scFv
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1;na
VD LC Kappa;Lambda
Highest_Clin_Trial (Jan '20) Phase-II/III
Est. Status Active
100% SI Structure 1bj1:HL:KJ/7v5n:BA:FE;None
99% SI Structure None;None
95-98% SI Structure 6bft:AB:HL/1cz8:HL:YX;None
Year Proposed 2024
Year Recommended na
Companies ABL Bio;Compass Therapeutics;Elpiscience Biopharmaceuticals;National OncoVenture;University of Texas M. D. Anderson Cancer Center;TRIGR Therapeutics
Conditions Approved na
Conditions Active Biliary cancer;Colorectal cancer
Conditions Discontinued Solid tumours
Production na
Development Tech na